The incidence of carcinoid syndrome in a population in central Sweden was estimated as being approximately 0.5 per 100,000 population per year.[1] Carcinoid syndrome occurs in patients with functional carcinoid tumours (i.e., symptoms are caused by hormonal release). There has been a clear rise in incidence of all gastroenteropancreatic neuroendocrine tumours (NETs) and specifically midgut carcinoid tumours, but the reasons for this are not clear.[2] The largest epidemiological study to date estimated the prevalence at 3.85 per 100,000 in the US population. The Surveillance, Epidemiology, and End Results (SEER) programme data from 1999 suggested a slight male sex bias of 1:1.14,[3] a preponderance in the age group in their sixth to seventh decade, and a greater incidence in black people and lower incidence in Asians and Hispanics than in white people.[4] Carcinoid tumours are the most common functional NET. While the incidence of NETs is relatively low at 5 per 100,000 population per year, the overall prevalence of this condition is much higher due to the relatively indolent nature of the disease. Estimated prevalence from the SEER database reports an approximate prevalence of 35 per 100,000 population of all NETs.[5]

BMJ Best Practice is an evidence-based point of care tool for healthcare practitioners.

To continue reading and access all of BMJ Best Practice's pages you'll need to log in or start a free trial.

You can access through your institution if your hospital, university, trust or other institution provides access to BMJ Best Practice through either OpenAthens or Shibboleth.

Use of this content is subject to our disclaimer